RARA Antibody
- Known as:
- RARA Antibody
- Catalog number:
- abx000697
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- RARA Antibody
Related genes to: RARA Antibody
- Gene:
- RARA NIH gene
- Name:
- retinoic acid receptor alpha
- Previous symbol:
- -
- Synonyms:
- RAR, NR1B1
- Chromosome:
- 17q21.2
- Locus Type:
- gene with protein product
- Date approved:
- 1988-06-09
- Date modifiied:
- 2019-04-23
Related products to: RARA Antibody
Related articles to: RARA Antibody
- - Source: PubMed
Publication date: 2026/09/22
Wu Hsin ChiehLaplantine EmmanuelEsnault CécileNiwa-Kawakita MichikoZhang YiDe Almeida Bastos VivianeGeoffroy Marie-Claudede Thé Hugues - RARA overexpression defines a molecularly distinct subset of acute myeloid leukemia (AML). Tamibarotene, an oral selective RARA agonist, synergizes with azacitidine (AZA) but its addition to venetoclax (VEN) with AZA has not been assessed. SY-1425-202 was a multicenter, open-label, randomized study evaluating tamibarotene combined to VEN/AZA (TAMI/VEN/AZA) vs VEN/AZA alone in newly diagnosed RARA-positive, unfit AML. Part 1 assessed the safety of TAMI/VEN/AZA, part 2 randomized participants to TAMI/VEN/AZA vs VEN/AZA, and part 3 explored salvage therapy with TAMI/VEN/AZA after VEN/AZA failure in part 2. TAMI 6 mg twice daily was administered. Randomization occurred after confirmation of RARA positivity by cycle 1, day 8. The primary end point was complete remission (CR) + CR with incomplete hematologic recovery (CRi) in part 2 and part 3, and safety in part 1. In part 1 (n=10), overall response rate (ORR) was 77.8% (5 CR, 2 CRi). In part 2 (n=51), CR/CRi was 60.0% for TAMI/VEN/AZA and 69.2% for VEN/AZA. Median CR/CRi duration was 293 vs 253 days. ORR was 80.0% vs 73.1%, respectively. In part 3, 2 of 5 patients responded (CR, morphologically leukemia-free state). Grade ≥3 treatment-emergent adverse event occurred in 76% of patients. Deaths were attributed mainly to disease progression or known complications of therapy; none were attributed to TAMI. The study met prespecified futility criteria and was discontinued early. The addition of TAMI to VEN/AZA was tolerable but did not improve efficacy over VEN/AZA. These results did not demonstrate clinical benefit of TAMI in the frontline unfit RARA-positive AML setting receiving VEN/AZA. This trial was registered at www.clinicaltrials.gov as #NCT04905407. - Source: PubMed
Publication date: 2026/07/28
Cluzeau ThomasBorate UmaMcMahon ChristineFenaux PierreHeiblig MaelPeterlin PierreBall BrianChantepie SylvainEghtedar AlirezaKambhampati SumanSolh MelhemTorregrosa-Diaz JoseBraun ThorstenDugan JamesFeld JonathanGourin Marie-PierrePigneux ArnaudRobin Jean-BaptisteSchiller GaryStein EytanRoth DavidKelly MichaelPollyea Danielde Botton Stephane - - Source: PubMed
Publication date: 2026/09/16
Shakibazad NaderShekarkhar Golsa - Successful implantation requires precise coordination of uterine epithelial receptivity, stromal decidualization, and immune homeostasis during a narrow peri-implantation window. Although retinoic acid (RA) signaling has been implicated in female reproduction, the endogenous and isoform-specific roles of retinoic acid receptors (RARs) remain poorly defined. Here, we combined isoform-specific genetic mouse models, transcriptomic profiling, and functional studies in mouse and human stromal cells to determine how RAR signaling regulates early pregnancy. We found that RARG is the dominant RAR isoform required for female fertility in mice, as its deletion severely impaired implantation, whereas combined loss of all RAR isoforms caused complete reproductive failure. RAR deficiency disrupted multiple sequential reproductive processes, including sperm transport and fertilization, suppression of uterine estrogen receptor activity, acquisition of stromal decidualization competence, and maintenance of uterine immune homeostasis. Transcriptomic analyses identified conserved epithelial and mesenchymal programs altered across independent RAR-deficient mouse models and revealed significant overlap with endometrial gene signatures from women with recurrent implantation failure. In human endometrial stromal cells, suppression of the RARA isoform consistently disrupted decidualization across three independent primary cell lines and an immortalized cell model. Together, these findings identify RAR signaling as a critical regulator of early pregnancy and reveal conserved, isoform-specific functions required for early pregnancy. - Source: PubMed
Publication date: 2026/09/10
Yin YanSo Emily YWolf ElianaRobles Pinos VivianHaller MeadeShang RenjieHewitt Sylvia CTak AlexBany Brent MChen David YShen MengchengDeMayo Francesco JMa Liang - Essential oils (EOs) are unique materials with healing powers that have been extensively reported. Yet their full antimicrobial potential is still underexplored due to their complex molecular properties, high viscosity, and low solubility, which limit their wide pharmaceutical application. In this study, we report the formulation of water-soluble nanoemulsions (NEs) of three EOs, namely, Artemisia vulgaris, Rhododendron anthopogon, and Eremophila mitchellii. The prepared NEs had an average particle diameter between 190 and 230 nm and remained physically stable at 4°C for up to 6 months. Most importantly, the fabricated NEs enhanced the antibacterial activity of the EOs against a multidrug-resistant Staphylococcus aureus clinical isolate by eightfold, with the EO having a median minimum inhibitory concentration (MIC) of 64 mg/mL, whilst the NEs had a median value of 8 mg/mL. Moreover, the NEs reduced the biofilm viability by up to > 6 log compared with the control groups. Among the tested EOs, E. mitchelli showed the strongest antibacterial activity, with MIC values of 16 and < 0.125 mg/mL for the EO and NE, respectively. In addition, E. mitchellii NE nearly eradicated S. aureus biofilms at 10 mg/mL across all strains. Safety studies against human foreskin fibroblasts indicated a harmless effect of the excipients used in the fabrication process, where the viability of cells exposed to the NEs of E. mitchellii and A. vulgaris was > 70% and 90%, respectively. These findings highlight the successful fabrication of EO-based NEs with potent antibacterial activity against multidrug-resistant S. aureus clinical isolates in vitro. - Source: PubMed
Karki SumeenaRamezanpour MahnazCooksley Clare MBarry EmmaPrestidge Clive ANepal RoshanFeizi SholehCorrell DianneWormald Peter-JohnVreugde SarahAwad Muhammed